Premium
Hot Features
Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions Galapagos will...
Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities Galapagos intends to create a new company with approximately €2.45 billion in cash...
Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company...
Mechelen, Belgium; January 7, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on...
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Data from the ongoing Phase...
Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile in all NHL subtypes...
New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs for patients with poor prognoses. Our innovative decentralized cell...
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024 New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in...
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster...
We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy.We are committed to addressing the high unmet needs of patients through a...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.22 | -0.95652173913 | 23 | 23.42 | 22.54 | 135855 | 23.04307782 | DE |
| 4 | -3.14 | -12.1141975309 | 25.92 | 31.08 | 22.54 | 171567 | 25.69506734 | DE |
| 12 | -3.72 | -14.0377358491 | 26.5 | 31.08 | 22.54 | 117251 | 25.54480262 | DE |
| 26 | -1.22 | -5.08333333333 | 24 | 31.08 | 22 | 108770 | 25.60206948 | DE |
| 52 | -11.56 | -33.6633663366 | 34.34 | 37.17 | 22 | 94217 | 26.88177764 | DE |
| 156 | -27.77 | -54.9357072206 | 50.55 | 66.28 | 22 | 155288 | 41.97505678 | DE |
| 260 | -194.62 | -89.5216191352 | 217.4 | 252.9 | 22 | 279503 | 87.33292194 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
3
